Drug intelligence / Profile preview

atriopeptin III

Development stage
Preclinical
Modality
Recombinant Proteins and Enzymes, Peptides
Administration
Intravenous, Subcutaneous (in Animal Studies; No Approved Clinical Formulation)
01

Overview

**Atriopeptin III** is a 24-amino acid peptide fragment (ANP 127-150) of rat atrial natriuretic peptide, functioning as a potent vasodilator, natriuretic, and diuretic agent[1][4][7]. Its primary mechanism is binding to natriuretic peptide receptors to induce vasodilation, promote sodium and water excretion, lower blood pressure, and increase glomerular filtration rate[1][3][5]. AP III demonstrates protective properties against ischemic acute renal failure and enhances cardiac relaxation by a mechanism involving endocardial endothelium[3][6][9]. Mostly characterized in animal models, it has been investigated for potential use in treating volume overload—including chronic renal failure, congestive heart failure, and possibly as a renal protective agent[1][3].

Other names
atrial natriuretic peptide (127-150)ANP (127-150)rat ANP (127-150)Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr
02

Targets

NPR1 (Natriuretic peptide receptor 1)NPR2 (C-type Natriuretic Peptide Receptor B)NPR3 (Natriuretic peptide receptor C)

Beyond the preview

Go deeper on atriopeptin III.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on atriopeptin III.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call